Therapy for recurrent malignant glioma in adults

Malignant gliomas are the most common form of primary brain tumors in adults. Although the prognosis remains poor, there has been recent progress in the treatment of these tumors. Standard therapy for patients with this disease will be reviewed, together with more novel approaches such as targeted molecular therapies, angiogenesis inhibitors, immunotherapies, gene therapiesand intratumoral therapies.

[1]  Susan M. Chang,et al.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2006, Neuro-oncology.

[2]  Susan M. Chang,et al.  Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study , 2005 .

[3]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[4]  Susan M. Chang,et al.  Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Susan M. Chang,et al.  Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs , 2004, Investigational New Drugs.

[6]  J. Uhm,et al.  Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma , 2004 .

[7]  R. Mirimanoff,et al.  Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group , 2004 .

[8]  M. Prados,et al.  A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs , 2004 .

[9]  G. Dresemann.  Imatinib (STI571) plus hydroxyurea: Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts) , 2004 .

[10]  M. Prados,et al.  Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Barnett,et al.  Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. J. van den Bent,et al.  Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Pichler,et al.  Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Hess,et al.  13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. , 2004, Neuro-oncology.

[15]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[16]  M. Rosenthal,et al.  BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide , 2004, Journal of Clinical Neuroscience.

[17]  A. Brandes,et al.  First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Bigner,et al.  Development of novel targeted therapies in the treatment of malignant glioma , 2004, Nature Reviews Drug Discovery.

[19]  M. Ciesielski,et al.  Immunotherapeutic strategies for malignant glioma. , 2004, Cancer control : journal of the Moffitt Cancer Center.

[20]  Keith L Black,et al.  Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. , 2004, Cancer control : journal of the Moffitt Cancer Center.

[21]  M. Zalutsky,et al.  Targeted radiotherapy of brain tumours , 2004, British Journal of Cancer.

[22]  A. Friedman,et al.  Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. , 2004, Neuro-oncology.

[23]  Susan M. Chang,et al.  Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. , 2004, Neuro-oncology.

[24]  U. Bogdahn,et al.  Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma , 2004, Cancer.

[25]  M. Chamberlain,et al.  Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide‐refractory glioblastoma multiforme , 2004, Cancer.

[26]  Raphael Pfeffer,et al.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. , 2004, Journal of neurosurgery.

[27]  Luther W Brady,et al.  Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. , 2004, International journal of radiation oncology, biology, physics.

[28]  V. Levin,et al.  Cyclooxygenase-2 Inhibitors in Glioma Therapy , 2004, American journal of therapeutics.

[29]  Erwin G. Van Meir,et al.  Replicative oncolytic herpes simplex viruses in combination cancer therapies. , 2004, Current gene therapy.

[30]  R. Soffietti.  Chemotherapy of anaplastic oligodendroglial tumours , 2004, Expert opinion on pharmacotherapy.

[31]  H. Newton.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis , 2004, Expert review of anticancer therapy.

[32]  M. Gruber,et al.  Temozolomide in Combination With Irinotecan for Treatment of Recurrent Malignant Glioma , 2004, American journal of clinical oncology.

[33]  T. Cloughesy,et al.  A Prospective Blinded Study of the Predictive Value of an Extreme Drug Resistance Assay in Patients Receiving CPT-11 for Recurrent Glioma , 2004, Journal of Neuro-Oncology.

[34]  Philippe Menei,et al.  Stereotaxic implantation of 5‐fluorouracil‐releasing microspheres in malignant glioma , 2004, Cancer.

[35]  S. Ryu,et al.  Association between Major Depressive Disorder and the –1438A/G Polymorphism of the Serotonin 2A Receptor Gene , 2004, Neuropsychobiology.

[36]  E. Aguilar-Córdova,et al.  Evolution of a Gene Therapy Clinical Trial , 2003, Journal of Neuro-Oncology.

[37]  F. Lang,et al.  Clinical Trials of Adenoviruses in Brain Tumors: A Review of Ad-p53 and Oncolytic Adenoviruses , 2003, Journal of Neuro-Oncology.

[38]  T. Lichtor,et al.  Cytokine Immuno-Gene Therapy for Treatment of Brain Tumors , 2003, Journal of Neuro-Oncology.

[39]  N. Rainov,et al.  Clinical Trials with Retrovirus Mediated Gene Therapy – what Have we Learned? , 2003, Journal of Neuro-Oncology.

[40]  D. Benos,et al.  Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[41]  Susan M. Chang,et al.  Treatment of Progressive or Recurrent Glioblastoma Multiforme in Adults with Herpes Simplex Virus Thymidine Kinase Gene Vector-Producer Cells Followed by Intravenous Ganciclovir Administration: A Phase I/II Multi-Institutional Trial , 2003, Journal of Neuro-Oncology.

[42]  I. Germano,et al.  Adenovirus/Herpes Simplex-Thymidine Kinase/Ganciclovir Complex: Preliminary Results of a Phase I trial in Patients with Recurrent Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[43]  L. Deangelis,et al.  High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma , 2003, Journal of Neuro-Oncology.

[44]  Susan M. Chang,et al.  A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors , 2003, Investigational New Drugs.

[45]  R. Puri,et al.  Interleukin-4-Pseudomonas Exotoxin Chimeric Fusion Protein for Malignant Glioma Therapy , 2003, Journal of Neuro-Oncology.

[46]  R. Puri,et al.  Interleukin-13 Receptor-Directed Cytotoxin for Malignant Glioma Therapy: From Bench to Bedside , 2003, Journal of Neuro-Oncology.

[47]  M. Berger,et al.  Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors , 2003, Journal of Neuro-Oncology.

[48]  H. Reulen,et al.  Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times , 2003, Journal of Neuro-Oncology.

[49]  A. Brandes,et al.  Non-cytotoxic Therapies for Malignant Gliomas , 2002, Journal of Neuro-Oncology.

[50]  N. Pavlakis,et al.  Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme , 2001, Journal of Neuro-Oncology.

[51]  M. Prados,et al.  Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study , 1997, Journal of Neuro-Oncology.

[52]  P. Forsyth,et al.  Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma , 1996, Journal of Neuro-Oncology.

[53]  Susan M. Chang,et al.  Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. , 2004, Journal of neurosurgery.

[54]  M. Kieran.  Anti-angiogenic chemotherapy in central nervous system tumors. , 2004, Cancer treatment and research.

[55]  T. Mikkelsen,et al.  Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. , 2004, Neuro-oncology.

[56]  Susan M. Chang,et al.  Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. , 2004, Neuro-oncology.

[57]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  H. Fine,et al.  A phase II trial of LY317615 in patients with recurrent high grade gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Buckner,et al.  NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  M. Rosenthal,et al.  Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. , 2004, Neuro-oncology.

[61]  G. Broggi,et al.  Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients , 2004, Journal of Neuro-Oncology.

[62]  G. Gillespie,et al.  Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents , 2004, Journal of Neuro-Oncology.

[63]  M. Chamberlain.  Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma Multiforme , 2004, Journal of Neuro-Oncology.

[64]  M. Gore,et al.  Thalidomide as an Anti-angiogenic Agent in Relapsed Gliomas , 2004, Journal of Neuro-Oncology.

[65]  Henry Brem,et al.  Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers , 2004, Investigational New Drugs.

[66]  P. Houghton,et al.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors , 2004, Cancer Chemotherapy and Pharmacology.

[67]  Susan M. Chang,et al.  Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2004, Neuro-oncology.

[68]  A. Brandes,et al.  State-of-the-art treatment of high-grade brain tumors. , 2003, Seminars in oncology.

[69]  C. Belka,et al.  Novel chemotherapeutic agents for the treatment of glioblastoma multiforme , 2003, Expert opinion on investigational drugs.

[70]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[72]  A. Tolcher,et al.  Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. , 2003, Seminars in oncology.

[73]  H. Newton.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways , 2003, Expert review of anticancer therapy.

[74]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[75]  R. Tanaka,et al.  Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial , 2003, British Journal of Cancer.

[76]  Susan M. Chang,et al.  33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma , 2003 .

[77]  M. Weller,et al.  Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  David E. Misek,et al.  Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. , 2003, The American journal of pathology.

[79]  J. Olson,et al.  An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. , 2003, Journal of neurosurgery.

[80]  M. Gilbert,et al.  Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[82]  E. Newlands,et al.  Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas , 2003, British Journal of Cancer.

[83]  Susan M. Chang,et al.  Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  E. Maher,et al.  Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Susan M. Chang,et al.  Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  C. Avezaat,et al.  Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[88]  Paul S Mischel,et al.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.

[89]  T. Mikkelsen,et al.  Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. , 2003, Cancer journal.

[90]  R. Jenkins,et al.  Recent advances in the molecular genetics of primary gliomas , 2003, Current opinion in oncology.

[91]  S. Spencer,et al.  Role of Radiation Therapy and Radiosurgery in Glioblastoma Multiforme , 2003, Cancer journal.

[92]  Susan M. Chang,et al.  Current Chemotherapy for Glioblastoma , 2003, Cancer journal.

[93]  N. Rainov,et al.  Gene Therapy for Human Malignant Brain Tumors , 2003, Cancer journal.

[94]  J. O'fallon,et al.  Irinotecan in the treatment of glioma patients , 2003, Cancer.

[95]  A. Olivi,et al.  Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  C. James,et al.  Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. , 2003, Frontiers in bioscience : a journal and virtual library.

[97]  T. Cloughesy,et al.  Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen , 2003, Cancer.

[98]  H. Friedman,et al.  Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma , 2003, Cancer.

[99]  M. Prados,et al.  A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. , 2003, Neuro-oncology.

[100]  Z. Ram,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[101]  M. J. van den Bent,et al.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors. , 2003, Neuro-oncology.

[102]  Xiangpeng Yuan,et al.  Current and future strategies for the treatment of malignant brain tumors. , 2003, Pharmacology & therapeutics.

[103]  L. Souhami,et al.  Stereotactic Radiosurgery in the Management of Intracranial Gliomas , 2003, Technology in cancer research & treatment.

[104]  R. Blasberg,et al.  In vivo imaging of molecular-genetic targets for cancer therapy. , 2003, Cancer cell.

[105]  E. Raymond,et al.  Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[107]  M. J. van den Bent,et al.  Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  Paul S Mischel,et al.  Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy , 2003, Cancer biology & therapy.

[109]  Y. Kondo,et al.  Current and Future Gene Therapy for Malignant Gliomas , 2003, Journal of biomedicine & biotechnology.

[110]  M. Mita,et al.  The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer , 2003, Cancer biology & therapy.

[111]  W. Elmquist,et al.  Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux , 2003, Journal of Pharmacology and Experimental Therapeutics.

[112]  K. Lillehei,et al.  Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[113]  M. Kris,et al.  Targeting lethal minimal residual disease in small cell lung cancer. , 2003, Seminars in oncology.

[114]  G. Konopka,et al.  Signaling pathways regulating gliomagenesis. , 2003, Current molecular medicine.

[115]  D. Resnick,et al.  Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  Paul S Mischel,et al.  Targeted Molecular Therapy of GBM , 2003, Brain pathology.

[117]  van den Bent Mj,et al.  Guidelines for the treatment of oligodendroglioma: an evidence-based medicine approach. , 2003 .

[118]  J. Nalbantoglu,et al.  Gene Therapy with Virus Vectors for specific Disease of the Nervous System: The Principles Of Molecular Therapies For Glioblastoma , 2003 .

[119]  R. Stupp,et al.  New drugs and combinations for malignant glioma. , 2003, Forum.

[120]  R Bucholz,et al.  Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. , 2003, Acta neurochirurgica. Supplement.

[121]  S. Hassenbusch,et al.  Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. , 2003, Neoplasia.

[122]  J. Nalbantoglu,et al.  The principles of molecular therapies for glioblastoma. , 2003, International review of neurobiology.

[123]  M. Westphal,et al.  Invasion as limitation to anti-angiogenic glioma therapy. , 2003, Acta neurochirurgica. Supplement.

[124]  M. Gilbert,et al.  Advances in molecular therapies in patients with brain tumors. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[125]  T. Moynihan.  Ependymal tumors , 2003, Current treatment options in oncology.

[126]  S. Kunwar.  Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. , 2003, Acta neurochirurgica. Supplement.

[127]  M. Westphal,et al.  Intracavitary chemotherapy for glioblastoma: present status and future directions. , 2003, Acta neurochirurgica. Supplement.

[128]  L. Aguilar,et al.  Evolution of a gene therapy clinical trial. From bench to bedside and back. , 2003, Journal of neuro-oncology.

[129]  M. J. van den Bent.  Guidelines for the treatment of oligodendroglioma: an evidence-based medicine approach. , 2003, Forum.

[130]  G. Barnett,et al.  Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. , 2003, Anticancer research.

[131]  S. Tatter.  Recurrent malignant glioma in adults , 2002, Current treatment options in oncology.

[132]  Susan M. Chang,et al.  Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. , 2002, International journal of radiation oncology, biology, physics.

[133]  J. Sampson,et al.  Clinical immunotherapy for brain tumors. , 2002, Neuroimaging clinics of North America.

[134]  A. Brandes,et al.  Is intra-arterial chemotherapy useful in high-grade gliomas? , 2002, Expert review of anticancer therapy.

[135]  A. Brandes,et al.  Current management and prognostic factors for adult ependymoma , 2002, Expert review of anticancer therapy.

[136]  J. Olson,et al.  The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. , 2002, Neurosurgery.

[137]  J. Olson,et al.  The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine , 2002, Neurosurgery.

[138]  A. Brandes,et al.  A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme , 2002, Neurology.

[139]  R. McLendon,et al.  Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  Susan M. Chang,et al.  A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. , 2002, Neuro-oncology.

[141]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[142]  R. Coleman,et al.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  K. Hess,et al.  Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  J. Dinnes,et al.  A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma , 2002, British Journal of Cancer.

[146]  B. Druker,et al.  Perspectives on the development of a molecularly targeted agent. , 2002, Cancer cell.

[147]  J. Raizer,et al.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. , 2002, Neuro-oncology.

[148]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[149]  M. Kieran,et al.  Antiangiogenesis therapy. Current and future agents. , 2001, Hematology/oncology clinics of North America.

[150]  R. McLendon,et al.  Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. , 2001, Neuro-oncology.

[151]  M. Prados.  Temozolomide in combination with other cytotoxic agents. , 2001, Seminars in oncology.

[152]  M. L. de Ceballos,et al.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. , 2001, Cancer research.

[153]  S. Nishikawa,et al.  Reovirus as an oncolytic agent against experimental human malignant gliomas. , 2001, Journal of the National Cancer Institute.

[154]  T. Shono,et al.  Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. , 2001, Cancer research.

[155]  P. Caliceti,et al.  Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. , 2001, Cancer biotherapy & radiopharmaceuticals.

[156]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[157]  O. Chinot,et al.  Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  D. B. Paul,et al.  Immunologic approaches to therapy for brain tumors , 2001, Current neurology and neuroscience reports.

[159]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[160]  B. Geoerger,et al.  Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.

[161]  K. Black,et al.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. , 2001, Cancer research.

[162]  M. J. van den Bent,et al.  PCV chemotherapy for recurrent glioblastoma multiforme , 2001, Neurology.

[163]  A. Brandes,et al.  High-Dose Chemotherapy with Bone Marrow Rescue for High-Grade Gliomas in Adults , 2001, Cancer investigation.

[164]  Hiroyuki Shimada,et al.  Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.

[165]  A. Alavi,et al.  Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. , 2001, Human gene therapy.

[166]  J. Sherley,et al.  Breaching the kinetic barrier to in vitro somatic stem cell propagation , 2001, Journal of biomedicine & biotechnology.

[167]  M Molls,et al.  A comparison of treatment results for recurrent malignant gliomas. , 2000, Cancer treatment reviews.

[168]  P. Black,et al.  Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.

[169]  D. Osoba,et al.  Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. , 2000, European journal of cancer.

[170]  P. Black,et al.  Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. , 2000, Cancer research.

[171]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[172]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[173]  J. Heimans,et al.  Survival of human glioma cells treated with various combination of temozolomide and X-rays. , 2000, International journal of radiation oncology, biology, physics.

[174]  W. Yung.  Temozolomide in malignant gliomas. , 2000, Seminars in oncology.

[175]  H. van Loveren,et al.  Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. , 2000, Neurosurgery.

[176]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[177]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[178]  J. Buckner,et al.  Chemotherapy for high-grade gliomas , 2000, British Journal of Cancer.

[179]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[180]  P. Wen,et al.  Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  W. Hall,et al.  Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. , 1999, International journal of radiation oncology, biology, physics.

[182]  E. Levin,et al.  Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing , 1999, Nature Medicine.

[183]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  M. Chamberlain,et al.  Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. , 1999, Archives of neurology.

[186]  R. McLendon,et al.  Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[187]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[188]  R. Mccomb,et al.  Pathology and Genetics of Tumours of the Nervous System , 1998 .

[189]  D. Louis,et al.  SPECIFIC CHROMOSOMAL LOSSES PREDICT CHEMOTHERAPEUTIC RESPONSE AND SURVIVAL IN PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMAS , 1998 .

[190]  M. Prados,et al.  Survival and functional status after resection of recurrent glioblastoma multiforme. , 1998, Neurosurgery.

[191]  M. McDermott,et al.  Interstitial brachytherapy for malignant brain tumors. , 1998, Seminars in surgical oncology.

[192]  Z. Ram,et al.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells , 1997, Nature Medicine.

[193]  H. Sandler,et al.  Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. , 1997, American journal of clinical oncology.

[194]  B. Jones,et al.  Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[195]  W. Yung,et al.  Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[196]  W. Hall,et al.  Stereotactic radiosurgery for recurrent malignant gliomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[198]  B. Scheithauer,et al.  Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. , 1995, Journal of neurosurgery.

[199]  P. Wen,et al.  Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. , 1995, Neurosurgery.

[200]  A. Guha,et al.  Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.

[201]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.

[202]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  J. Schwade,et al.  Retreatment of Intracranial Gliomas , 1994, Southern medical journal.

[204]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[205]  M. Apuzzo,et al.  Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. , 1993, Neurosurgery.

[206]  R. Schwartz,et al.  Primary brain tumors in adults. , 1992, Seminars in ultrasound, CT, and MR.

[207]  B. Jeremic,et al.  Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  David W. Smith,et al.  The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. , 1992, Journal of neurosurgery.

[209]  P. Gutin,et al.  Selection bias, survival, and brachytherapy for glioma. , 1992, Journal of neurosurgery.

[210]  L. Junck,et al.  Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure , 1990, Neurology.

[211]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[212]  P. Wen,et al.  Malignant gliomas , 1981, Neuro-Chirurgie.

[213]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.